The biopharmaceutical company ONCOMATRYX Biopharma and Leitat are collaborating in the NEXTOM project, which aims to develop new Antibody Drug Conjugates (ADCs) targeting the tumor microenvironment. This approach represents a novel strategy in oncology to improve the effectiveness of current cancer treatments, particularly in their most invasive and metastatic stages. ADCs are an emerging class of highly potent pharmaceutical compounds that offer an innovative combination of chemotherapy and immunotherapy.
Through this project, ONCOMATRYX will be able to obtain new ADCs to enhance the efficacy of immuno-oncological treatments in their most aggressive stages. Leitat, in turn, will expand its portfolio of animal models in oncology and contribute its expertise in preclinical and bioanalytical development. By the end of the NEXTOM project, the best ADC therapeutic candidate will be selected to continue with industrial and clinical development.
As part of the NEXTOM project, a first in-person meeting was held on February 5 at ONCOMATRYX’s facilities, where the project status was updated and the next steps were defined to achieve the objectives set.
